Tarsons Q1 FY27 Results: Revenue up 21%, PAT rises 28%
TARSONS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Tarsons Products reported Q1 FY27 consolidated revenue of Rs 1,102 million, up 21% YoY from Rs 914 million. Consolidated PAT rose 28% to Rs 22.76 million. Standalone revenue grew 21% to Rs 861 million with PAT at Rs 6.86 million. Board fixed September 24, 2026 for the 43rd AGM. Company also disclosed paying Rs 41.39 million excess managerial remuneration to directors in FY26 and is seeking shareholder waiver.
Revenue and profit growth signal improving demand. Watch AGM item seeking waiver for excess director pay of about Rs 41 million.